Health technology assessment and personalized medicine: Are economic evaluation guidelines sufficient to support decision making?

International Journal of Technology Assessment in Health Care

Volumn 30, Issue 2, 2014, Pages 179-187

  Husereau, Don ^a,f,g   Marshall, Deborah A ^b   Levy, Adrian R ^c   Peacock, Stuart ^d,h   Hoch, Jeffrey S ^e  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^e CANCER CARE ONTARIO   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomedical; Biomedical research methods; Biomedical research standards; Costs and cost analysis; Decision support techniques; Delivery of health care; Diagnostic techniques and procedures; Health policy; Humans; Individualized medicine methods; Technology assessment

Indexed keywords

COSTS; DECISION MAKING; DECISION SUPPORT SYSTEMS;

BIOMEDICAL; BIOMEDICAL RESEARCH; COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DELIVERY OF HEALTH CARE; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE/METHODS; TECHNOLOGY ASSESSMENTS;

ECONOMIC ANALYSIS;

ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; MEDICAL ASSESSMENT; MEDICAL TECHNOLOGY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; STANDARDS;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; PRECISION MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84902073017     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462314000142     Document Type: Article

References (41)

1. Tarn T, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connect. 2004;10:5-15.
2. Eldessouki R, Dix Smith M. Health care system information sharing: A step toward better health globally. Value Health Regional Issues. 2012;1:118-120.
3. Mittmann N, Evans WK, Rocchi A, et al. Guidelines for health technologies: Specific guidance for oncology products in Canada. Value Health. 2012;15:580-585.
4. Drummond MF, Sculpher MJ, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. Cambridge: Oxford University Press; 2005.
5. Faulkner E, Annemans L, Garrison L, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR personalized medicine special interest group. Value Health. 2012;15:1162-1171.
6. Stallings SC, Huse D, Finkelstein SN, et al. A framework to evaluate the economic impact of pharmacogenomics. Pharmacogenomics. 2006;7:853-862.
7. Repa R. The power of innovation. Ontario: Hamilton; 2010.
8. The Lewin Group. Under the microscope: Trends in laboratory medicine [Internet]. Oakland: California Healthcare Foundation; 2009. www.chcf.org (accessed December 25, 2013).
9. Becla L, Lunshof JE, Gurwitz D, et al. Health technology assessment in the era of personalized health care. Int J Technol Assess Health Care. 2011;27:118-126.
10. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration. Clin Chem. 2003;49:7-18.
11. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP working group. Genet Med. 2009;11:3-14.
12. Fang C, Otero HJ, Greenberg D, Neumann PJ. Cost-utility analyses of diagnostic laboratory tests: A systematic review. Value Health. 2011;14:1010-1018
13. CADTH. Guidelines for the economic evaluation of health technologies. Canada: Canadian Agency for Drugs and Technologies in Health; 2006. 46 p.
14. Beaulieu M, de Denus S, Lachaine J. Systematic review of phar-macoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010;11:1573-1590.
15. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost Effectiveness of Pharmacogenomics. Pharmacoeconomics. 2010;28:1001-1013.
16. Paci D, Ibarreta D. Economic and cost-effectiveness considerations for pharmacogenetics tests: An integral part of translational research and innovation uptake in personalized medicine. Curr Pharmacogenomics Person Med. 2009;7:284-96.
17. Mittmann N, Au H-J, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst. 2009;101:1182-1192.
18. Health Quality Ontario. KRAS Testing for anti-EGFR therapy in advanced colorectal cancer: An evidence-based and economic analysis. Ont Health Technol Assess Ser. 2010;10:1-49.
19. Dranitsaris G, Norris B, Hanna W, O'Malley F, Gelmon K. Identifying the optimal timing of HER2/neu testing in patients with breast cancer: A Canadian cost minimization analysis. Breast Cancer Res Treat. 2002;76:S135-S135.
20. Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: A systematic review and cost-effectiveness analysis. CMAJ. 2007;176:1429-1434.
21. Paulden M, Franek J, Pham B, Krahn M. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: A Cost-effectiveness analysis of 1000 strategies for the provision of adjuvant! Online, Oncotype Dx and Chemotherapy. Value Health. 2011;14A167-A167.
22. Hannouf MB, Xie B, Brackstone M, Zaric GS. Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen-or progesterone-receptor-positive, axillary lymph-node negative breast cancer. BMC Cancer. 2012;12:447.
23. Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. Med Decis Making. 2007;27:112-127.
24. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics. Pharmacoeconomics. 2010;28:1001-1013.
25. IOM (Institute of Medicine). The economics of genomic medicine: Workshop summary. Washington, DC: The National Academies Press; 2013.
26. Elkin EB, Marshall DA, KulinNA, et al. Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genet Med. 2011;13:853-860.
27. Ferrusi IL, LeighlNB, KulinNA, Marshall DA. Do economic evaluations of targeted therapy provide support for decision makers? J Oncol Pract. 2011;7:36s-45s.
28. Postma MJ, Boersma C, Vandijck D, et al. Health technology assessments in personalized medicine: Illustrations for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2011;11:367-369.
29. Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health. 2013;16:S20-S26.
30. Personalized Medicine Coalition. The case for personalized medicine, 3rd ed [Internet]. Personalized Medicine Coalition. http://www.ageof personalizedmedicine.org/objects/pdfs/Case-for-PM-3rd-edition.pdf (accessed October 26, 2012).
31. Lee DW, Neumann PJ, Rizzo JA. Understanding the medical and non-medical value of diagnostic testing. Value Health. 2010;13:310-314.
32. Birch S, Donaldson C. Valuing the benefits and costs of health care programmes: Where's the "extra" in extra-welfarism? Soc Sci Med. 2003;56:1121-1133.
33. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005;24:751-773.
34. Merlin T, Farah C, Schubert C, et al. Assessing personalized medicines in Australia: A national framework for reviewing codependent technologies. Med Decis Making. 2013;33:333-342.
35. Australian Government Department of Health and Ageing. Section D: Economic evaluation for the main indication [Internet]. http://www.pbs.gov.au/ info/industry/listing/elements/pbac-guidelines/b-part-2/Section-D (accessed October 26, 2012).
36. Elkin EB, Marshall DA, Kulin NA, et al. Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genet Med. 2011;13:853-860.
37. Basu A. Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care. J Health Econ. 2011;30:549-559.
38. Ferrusi IL, Earle CC, Trudeau M, et al. Closing the personalized medicine information gap: HER2 test documentation practice. Am J Manag Care. 2013;19:838-844.
39. Basu A, Heckman JJ, Navarro-Lozano S, Urzua S. Use of instrumental variables in the presence of heterogeneity and self-selection: An application to treatments of breast cancer patients. Health Econ. 2007;16:1133-1157.
40. NICE. Diagnostics Assessment Programme manual [Internet]. NICE. [cited 2014 Jan 6]. http://www.nice.org.uk/(accessed January 6, 2014).
41. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Tech-nol Assess Health Care. 2013;29:117-122.